美国食品药品监督管理局（FDA）正试图撤回对一种由加州生物技术公司 ChemoCentryx 开发的实验性血管炎药物的批准，这一过程被描述为并非易事 1。2021年5月发布的简报文件显示，尽管该药物旨在治疗常损害肾脏和肺部的罕见自身免疫性血管炎，但 FDA 咨询委员会认为研究设计不理想，导致临床试验数据难以解读且药物疗效未得到充分验证 1。
然而，在监管评估与临床现实之间存在分歧，部分患者及医生认为该药物可能帮助减少对高副作用类固醇药物的依赖 1。
The U.S. Food and Drug Administration is navigating a difficult process as it considers withdrawing its approval of a drug developed by California-based biotechnology company ChemoCentryx 1. The medication is indicated for treating a rare form of autoimmune vasculitis that frequently damages the kidneys and lungs 1. In May 2021, the agency released briefing documents regarding this experimental treatment, marking a critical stage in its evaluation and consideration of revocation 1.
Despite the FDA’s concerns, the situation remains nuanced due to conflicting assessments of the drug’s efficacy. An FDA advisory committee determined that the clinical trials suffered from design flaws, making the data difficult to interpret and leaving the drug’s effectiveness insufficiently verified 1. However, some patients and medical professionals argue that the therapy offers significant benefits, specifically by helping reduce reliance on steroids, which are associated with severe side effects 1.
评论
还没有评论，欢迎留下第一条。